Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration

Abstract Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, espe...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bokyeong Lee, Minjee Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-10-01
Col·lecció:	Scientific Reports
Matèries:	Infliximab Inflammatory bowel disease Subcutaneous administration Transition therapy Inadequate response
Accés en línia:	https://doi.org/10.1038/s41598-024-75693-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!